Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Filed Feb 4, 2025 · 10-K · 35 days after period end · 0001493152-25-004872
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023 |
|---|---|---|
| Net Income | -$2.90M | -$9.33M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Feb 4, 2025 · 35 d after period end
